Prognostic factors of metastatic myxoid liposarcoma

BMC Cancer

Hiroshi Kobayashi¹  Naofumi Asano²  Hideo Morioka²  Robert Nakayama²  Hirotaka Kawano³  Yusuke Shinoda⁴  Akira Kawai⁵  Tomoaki Mori⁶  Eisuke Kobayashi⁶  Shintaro Iwata⁷  Tohru Hiruma⁸  Tsukasa Yonemoto⁹  Takeshi Ishii⁹ 

[1] Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan;Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan;Department of Orthopaedic Surgery, Teikyo University School of Medicine, Tokyo, Japan;Department of Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan;Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan;Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan;Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan;Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan;Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan;Division of Orthopaedic Surgery, Chiba Cancer Center, Chiba, Japan;Division of Musculoskeletal Tumor Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan;Division of Orthopaedic Surgery, Chiba Cancer Center, Chiba, Japan;

关键词: Myxoid liposarcoma;    Metastasis;    Prognostic factor;   

DOI  :  10.1186/s12885-020-07384-1

来源: Springer

【 摘 要 】

BackgroundMyxoid liposarcoma (MLS) has the tendency to metastasize extrapulmonary. Although prognostic factors at the initial diagnosis of MLS have been reported, those at diagnosis of metastasis remain unclear. The purpose of this study was to investigate the prognostic factors for disease-specific survival at the initial diagnosis of metastasis.MethodsThis retrospective observational study was conducted at three cancer centers and two university hospitals in Japan. Of 274 MLS patients pathologically diagnosed between 2001 and 2015, 48 metastatic patients were examined.ResultsLung metastases were detected in nine patients (18.8%) and extrapulmonary metastases in 45 (93.8%). Interval from primary diagnosis to the first metastasis was significantly shorter in patients with lung metastases than without (p = 0.007). Median disease-specific survival after diagnosis of metastases was 52.5 months in all patients. In multivariable analysis, liver metastasis (hazard ratio (HR), 2.71 [95% confidence interval (CI), 1.00–7.09]) and no evidence of disease (NED) achieved by radical treatment (resection with or without radiation therapy, or radiation therapy ≥60 Gy) or semi-radical (radiation therapy ≥40 Gy) treatment were significantly related to survival (HR, 0.36; 95%CI [0.13–0.95]). The number of metastases (odds ratio (OR), 0.44; 95%CI [0.25–0.78]) and abdominal/retroperitoneal metastases (OR, 0.09; 95%CI [0.008–0.95]) were the significant inhibitory factors of achieving NED.ConclusionsThis is the first study to statistically demonstrate the importance of achieving NED with surgical resection or radiation therapy for longer survival in metastatic MLS patients. As number of metastases was a significant factor for achieving NED, early detection of metastases might be important.

【 授权许可】

CC BY